RPS19 and neoplasm: We then used Enzyme-Linked ImmunoSpot (ELISPOT) and flow cytometry to determine the antitumor immunity of CT26 tumor-bearing mice treated with Hf12-DBA-mediated RT plus anti-PD-L1 antibody.